Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award Framework Agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see Section II.2.11).
Tenders for the pharmaceuticals are invited so that the Contracting Authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4).
The Framework Agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework Agreement.
Deadline
Fristen for modtagelse af bud var på 2019-05-21.
Indkøbet blev offentliggjort på 2019-04-08.
Leverandører
Følgende leverandører er nævnt i tildelingsbeslutninger eller andre indkøbsdokumenter:
Ordregivende myndighed
E-mail: eirik.sverrisson@sykehusinnkjop.no📧
Region: Norge 🏙️
URL: http://www.sykehusinnkjop.no🌏 Oplysninger om fælles indkøb
Kontrakten omfatter fælles indkøb
I tilfælde af fælles indkøb, der involverer forskellige lande, angives den gældende nationale udbudslovgivning: Danish law
Kommunikation
URL til dokumenter: www.amgros.dk🌏
Objekt Omfanget af udbuddet
Titel: Joint Nordic Procurement of Pharmaceuticals — 2020 — NF1.620.a
Produkter/tjenester: Lægemidler📦
Kort beskrivelse:
“Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award...”
Kort beskrivelse
Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award Framework Agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see Section II.2.11).
Tenders for the pharmaceuticals are invited so that the Contracting Authorities can enter into Framework Agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4).
The Framework Agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework Agreement.
Vis mere
Anslået værdi uden moms: EUR 11 100 000 💰
Oplysninger om partier
Der kan afgives bud for alle partier
1️⃣ Omfanget af udbuddet
Titel: 1
Titel
Partiets identifikationsnummer: 1
Beskrivelse
Yderligere produkter/tjenester: Lægemidler📦
Sted for udførelsen: Danmark🏙️
Sted for udførelsen: Ísland 🏙️
Sted for udførelsen: Norge 🏙️
Beskrivelse af udbuddet:
“Procurement No: 1
ATC Code: A04AA01
Generic name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strength: 2 mg/ml
Package: 2 ml
Unit value: 16 mg
Volume...”
Beskrivelse af udbuddet
Procurement No: 1
ATC Code: A04AA01
Generic name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strength: 2 mg/ml
Package: 2 ml
Unit value: 16 mg
Volume in units: (Iceland: 1029) (Norway: 50000) (Denmark: 93478).
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding and “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).
Vis mere Kriterier for tildeling
Pris
Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 1 050 000 💰
Varighed
Startdato: 2020-02-01 📅
Slutdato: 2021-01-31 📅
Kontraktens, rammeaftalens eller det dynamiske indkøbssystems varighed
Denne kontrakt kan forlænges ✅ Beskrivelse
Beskrivelse af fornyelser:
“The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by...”
Beskrivelse af fornyelser
The Contracting Authorities shall be entitled to extend the Framework Agreement up to 2 times for each pharmaceutical on unchanged terms and conditions by up to 6 months.
Vis mere Oplysninger om valgmuligheder
Indstillinger ✅
Beskrivelse af mulighederne:
“Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for...”
Beskrivelse af mulighederne
Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 3 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.
For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.
If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.
2️⃣ Omfanget af udbuddet
Titel: 2
Titel
Partiets identifikationsnummer: 2
Beskrivelse
Beskrivelse af udbuddet:
“Procurement No: 2
ATC Code: A04AA01
Generic name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strength: 2 mg/ml
Package: 4 ml
Unit value: 16 mg
Volume...”
Beskrivelse af udbuddet
Procurement No: 2
ATC Code: A04AA01
Generic name: Ondansetrone
Pharmaceutical form: Injection Fluid
Strength: 2 mg/ml
Package: 4 ml
Unit value: 16 mg
Volume in units: (Iceland: 329) (Norway: 15000) (Denmark: 16625).
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding and “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 200 000 💰
Oplysninger om valgmuligheder
Beskrivelse af mulighederne:
“Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for...”
Beskrivelse af mulighederne
Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.
For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.
If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.
3️⃣ Omfanget af udbuddet
Titel: 3
Titel
Partiets identifikationsnummer: 3
Beskrivelse
Beskrivelse af udbuddet:
“Procurement No: 3
ATC Code: J01GB03
Generic name: Gentamicin
Pharmaceutical form: Infusion Fluid
Strength: 1 mg/ml
Unit value: 0,24 g
Volume in units:...”
Beskrivelse af udbuddet
Procurement No: 3
ATC Code: J01GB03
Generic name: Gentamicin
Pharmaceutical form: Infusion Fluid
Strength: 1 mg/ml
Unit value: 0,24 g
Volume in units: (Iceland: 47) (Norway: 6667) (Denmark: 903)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 250 000 💰
Oplysninger om valgmuligheder
Beskrivelse af mulighederne:
“Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for...”
Beskrivelse af mulighederne
Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the Framework Agreement and in the tender specifications.
For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.
If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.
4️⃣ Omfanget af udbuddet
Titel: 4
Titel
Partiets identifikationsnummer: 4
Beskrivelse
Beskrivelse af udbuddet:
“Procurement No: 4
ATC Code: J01GB03
Generic name: Gentamicin
Pharmaceutical form: Infusion Fluid
Strength: 3 mg/ml
Package: 80 ml
Unit value: 0,24 g
Volume...”
Beskrivelse af udbuddet
Procurement No: 4
ATC Code: J01GB03
Generic name: Gentamicin
Pharmaceutical form: Infusion Fluid
Strength: 3 mg/ml
Package: 80 ml
Unit value: 0,24 g
Volume in units: (Iceland: 60) (Norway: 33000) (Denmark: 4750).
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 1 850 000 💰
5️⃣ Omfanget af udbuddet
Titel: 5
Titel
Partiets identifikationsnummer: 5
Beskrivelse
Beskrivelse af udbuddet:
“Procurement No: 5
ATC Code: J01GB03
Generic name: Gentamicin
Pharmaceutical form: Infusion Fluid
Strength: 3 mg/ml
Package: 120 ml
Unit value: 0,24 g
Volume...”
Beskrivelse af udbuddet
Procurement No: 5
ATC Code: J01GB03
Generic name: Gentamicin
Pharmaceutical form: Infusion Fluid
Strength: 3 mg/ml
Package: 120 ml
Unit value: 0,24 g
Volume in units: (Iceland: 64) (Norway: 39000) (Denmark: 17205).
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 500 000 💰
Oplysninger om valgmuligheder
Beskrivelse af mulighederne:
“Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for...”
Beskrivelse af mulighederne
Clause 1 of the Framework Agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the framework agreement and in the tender specifications.
For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a Framework Agreement, the Framework Agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.
If the supplier chooses not to give a tender for the delivery to Iceland the Framework Agreement will cover delivery of the pharmaceuticals in Denmark and Norway.
6️⃣ Omfanget af udbuddet
Titel: 6
Titel
Partiets identifikationsnummer: 6
Beskrivelse
Beskrivelse af udbuddet:
“Procurement No: 6,
ATC Code: N02BE01
Generic name: Paracetamol
Pharmaceutical form: Infusion Fluid
Strength: 10 mg/ml
Package: 10-50 ml
Unit value: 3...”
Beskrivelse af udbuddet
Procurement No: 6,
ATC Code: N02BE01
Generic name: Paracetamol
Pharmaceutical form: Infusion Fluid
Strength: 10 mg/ml
Package: 10-50 ml
Unit value: 3 g
Volume in units: (Iceland: 1) (Norway: 21667) (Denmark: 1817).
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 4 850 000 💰
7️⃣ Omfanget af udbuddet
Titel: 7
Titel
Partiets identifikationsnummer: 7
Beskrivelse
Beskrivelse af udbuddet:
“Procurement No: 7
ATC Code: N02BE01
Generic name: Paracetamol
Pharmaceutical form: Infusion Fluid
Strength: 10 mg/ml
Package: 100 ml
Unit value: 3 g
Volume...”
Beskrivelse af udbuddet
Procurement No: 7
ATC Code: N02BE01
Generic name: Paracetamol
Pharmaceutical form: Infusion Fluid
Strength: 10 mg/ml
Package: 100 ml
Unit value: 3 g
Volume in units: (Iceland: 880) (Norway: 21667) (Denmark: 10688).
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for 1, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title “quantity in units”, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a Framework Agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), “Farmalogg” (Norway) and “Lyfjaverðskrá” (Iceland) no later than 1.12.2019. The requirement regarding “Lyfjaverðskrá” (Iceland) only apply if Iceland is part of the Framework Agreement, see Section II.2.11).
Vis mere Omfanget af udbuddet
Anslået samlet værdi ekskl. moms: EUR 2 400 000 💰
Juridiske, økonomiske, finansielle og tekniske oplysninger Betingelser for deltagelse
Liste og kortfattet beskrivelse af betingelserne:
“Suppliers wishing to submit tender must use the standard form of the European Single Procurement Document (ESPD) for the declaration regarding the...”
Liste og kortfattet beskrivelse af betingelserne
Suppliers wishing to submit tender must use the standard form of the European Single Procurement Document (ESPD) for the declaration regarding the compulsory grounds for exclusion set out in Sections 135-136 of the Danish Public Procurement Act (udbudsloven) (Act No 1564 of 15.12.2015 as amended). Further information on the completion and application of the ESPD in the tender process is available in the guide drawn up by Amgros in this respect and in the "Instructions for the European Single Procurement Document" drawn up by the Danish Competition and Consumer Authority (Konkurrence- og Forbrugerstyrelsen). The successful tenderer(s) to whom the Contracting Authorities intends to award the Framework Agreement must also, before the award, provide documentation to the Contracting Authorities regarding the absence of compulsory grounds for exclusion as set out in Sections 152-153 of the Public Procurement Act. The Contracting Authorities is not entitled to exclude a supplier who is subject to 1 or more of the mandatory exclusion grounds set out in Sections 135-136 of the Public Procurement Act if the supplier has provided sufficient documentation that the supplier is reliable, even if the supplier is subject to 1 or more of the grounds for exclusion set out in Section 138 of the Public Procurement Act. The Contracting Authorities reserves the right to carry out a so-called “self-cleaning” process if relevant.
Vis mere Økonomisk og finansiel stilling
Liste og kortfattet beskrivelse af udvælgelseskriterier: No information required.
Teknisk og faglig kompetence
Liste og kortfattet beskrivelse af udvælgelseskriterier: No information required.
Betingelser i forbindelse med kontrakten
Betingelser for opfyldelse af kontrakten:
“Reference is made to the provisions of the draft Framework Agreement and Section II.2.4).
No specific legal form is required. If the contract is awarded to...”
Betingelser for opfyldelse af kontrakten
Reference is made to the provisions of the draft Framework Agreement and Section II.2.4).
No specific legal form is required. If the contract is awarded to a group of suppliers, each participant must undertake joint and several liability and appoint a joint representative.
Procedure Type af procedure
Åben procedure
Oplysninger om en rammeaftale eller et dynamisk indkøbssystem
Rammeaftale med en enkelt operatør
Administrative oplysninger
Frist for modtagelse af bud eller ansøgninger om deltagelse: 2019-05-21
12:00 📅
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: dansk 🗣️
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: norsk 🗣️
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: svensk 🗣️
Sprog, på hvilke bud eller ansøgninger om deltagelse kan indgives: engelsk 🗣️
Betingelser for åbning af buddene: 2019-05-21
12:00 📅
Betingelser for åbning af buddene (sted): Amgros I/S, Dampfærgevej 27-29, DK-2100 Copenhagen Ø.
Betingelser for åbning af tilbud (Oplysninger om bemyndigede personer og åbningsprocedure):
“The tenderers are not permitted to attend the opening of the tenders. Tenders will be registered upon receipt, and tenders received on time will be opened...”
Betingelser for åbning af tilbud (Oplysninger om bemyndigede personer og åbningsprocedure)
The tenderers are not permitted to attend the opening of the tenders. Tenders will be registered upon receipt, and tenders received on time will be opened collectively after expiry of the deadline for submission of tenders.
Supplerende oplysninger Oplysninger om elektroniske arbejdsgange
Der vil blive anvendt elektronisk bestilling
Elektronisk fakturering vil blive accepteret
Yderligere oplysninger
“This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to...”
This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud), see Section VI.4.3).
In relation to Section II.2.4) it should be noted that the Contracting Authorities has considered whether the procurement group can be further subdivided. The Contracting Authorities has assessed that this is not the case on the basis of considerations of economies of scale which will not be realisable in case of a further subdivision, as well as costs and patient safety considerations related to the subsequent management of contract and pharmaceuticals.
In relation to Sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in Section II.1.5) is the total estimated value of all procurement numbers (lots) for the duration of the Framework Agreement, including the option of renewal, see Section II.2.7). Section II.2.6) sets out the estimated value for each procurement number, including the option of renewal, see Section II.2.7). The value is based on the AIP (“Apotekernes Indkøbspris” published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a Framework Agreement may differ significantly from the estimate, see Section II.2.4), Paragraph 3.6 of the tender specifications and Clause 2 of the Framework Agreement.
Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard.
The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide.
In relation to Section VI.2) it should be noted that electronic invoicing is required.
Vis mere Gennemgå organ
Navn: Klagenævnet for Udbud
Postadresse: Nævnenes Hus, Toldboden 2
Postby: Viborg
Postnummer: 8800
Land: Danmark 🇩🇰
Telefon: +45 35291095📞
E-mail: klfu@erst.dk📧
URL: https://erhvervsstyrelsen.dk/klagenaevnet-for-udbud🌏 Gennemgangsprocedure
Præcise oplysninger om fristerne for gennemgangsprocedurer:
“Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act No 593 of 2.6.2016 as amended) the following deadlines apply to the lodging...”
Præcise oplysninger om fristerne for gennemgangsprocedurer
Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act No 593 of 2.6.2016 as amended) the following deadlines apply to the lodging of complaints:
Complaints of the tendering procedure must be lodged with the Complaints Board for Public Procurement within 6 months after the contracting entity has entered into a Framework Agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see Section 7(2), Para. (3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see Section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.
Vis mere Tjeneste, hvorfra der kan indhentes oplysninger om klageproceduren
Navn: Konkurrence- og Forbrugerstyrelsen
Postadresse: Carl Jacobsens vej 35
Postby: Valby
Postnummer: 2500
Land: Danmark 🇩🇰
Telefon: +45 41715000📞
URL: http://www.kfst.dk🌏
Kilde: OJS 2019/S 073-172191 (2019-04-08)
Bekendtgørelse om indgåede kontrakter (2019-08-12) Ordregivende myndighed Oplysninger om fælles indkøb
I tilfælde af fælles indkøb, der involverer forskellige lande, angives den gældende nationale udbudslovgivning: Danish law.
Objekt Omfanget af udbuddet
Kort beskrivelse:
“Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award...”
Kort beskrivelse
Denmark, Norway and Iceland have entered into cooperation regarding the procurement of pharmaceuticals. The countries will jointly procure and award framework agreements in order to ensure the supply of pharmaceuticals to the public hospitals and health authorities in the countries. In Denmark certain pharmaceuticals is resold to the Faroe Island and Greenland. For this procurement group delivery to Iceland is an option, see Section II.2.11).
Tenders for the pharmaceuticals are invited so that the contracting authorities can enter into framework agreements for delivery of the pharmaceuticals requested in the list of products and specified under the various lots below (Section II.2.4).
The framework agreements are non-exclusive to the supplier. The hospitals and health authorities are not obliged to use the Framework agreement.
Vis mere
Samlet værdi af indkøbsaftalen (ekskl. moms): EUR 6 720 000 💰
Oplysninger om partier
Denne kontrakt er opdelt i partier ✅ Beskrivelse
Beskrivelse af udbuddet:
“Procurement No 1,
ATC Code: A04AA01,
Generic name: Ondansetrone,
Pharmaceutical form: injection fluid,
Strength: 2 mg/ml,
Package: 2 ml,
Unit value: 16...”
Beskrivelse af udbuddet
Procurement No 1,
ATC Code: A04AA01,
Generic name: Ondansetrone,
Pharmaceutical form: injection fluid,
Strength: 2 mg/ml,
Package: 2 ml,
Unit value: 16 mg,
Volume in units: (Iceland: 1029)(Norway: 50000)(Denmark: 93478)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding and ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere Oplysninger om valgmuligheder
Beskrivelse af mulighederne:
“Clause 1 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for...”
Beskrivelse af mulighederne
Clause 1 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the framework agreement and in the tender specifications.
For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the supplier is awarded a framework agreement the framework agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.
If the supplier chooses not to give a tender for the delivery to Iceland the framework agreement will cover delivery of the pharmaceuticals in Denmark and Norway.
Vis mere Beskrivelse
Beskrivelse af udbuddet:
“Procurement No 2,
ATC Code: A04AA01,
Generic name: Ondansetrone,
Pharmaceutical form: injection fluid,
Strength: 2 mg/ml,
Package: 4 ml,
Unit value: 16...”
Beskrivelse af udbuddet
Procurement No 2,
ATC Code: A04AA01,
Generic name: Ondansetrone,
Pharmaceutical form: injection fluid,
Strength: 2 mg/ml,
Package: 4 ml,
Unit value: 16 mg,
Volume in units: (Iceland: 329)(Norway: 15000)(Denmark: 16625)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding and ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere Oplysninger om valgmuligheder
Beskrivelse af mulighederne:
“Clause 1 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for...”
Beskrivelse af mulighederne
Clause 1 of the framework agreement provides for an option for delivery in a pre-agreement period (i.e. before the purchase period begins) and an option for delivery in a post-agreement period (i.e. after the purchase period). The 2 options may be exercised on the terms and conditions stipulated in the framework agreement and in the tender specifications.
For this procurement group delivery to Iceland is an option. The supplier can choose to submit a tender for this option. If the Supplier is awarded a framework agreement the framework agreement will cover delivery of the pharmaceuticals in all 3 countries for the purchase period.
If the supplier chooses not to give a tender for the delivery to Iceland the framework agreement will cover delivery of the pharmaceuticals in Denmark and Norway.
Vis mere Beskrivelse
Beskrivelse af udbuddet:
“Procurement No 3,
ATC Code: J01GB03,
Generic name: Gentamicin,
Pharmaceutical form: infusion fluid,
Strength: 1 mg/ml,
Unit value: 0,24 g,
Volume in units:...”
Beskrivelse af udbuddet
Procurement No 3,
ATC Code: J01GB03,
Generic name: Gentamicin,
Pharmaceutical form: infusion fluid,
Strength: 1 mg/ml,
Unit value: 0,24 g,
Volume in units: (Iceland: 47)(Norway: 6667)(Denmark: 903)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere
Beskrivelse af udbuddet:
“Procurement No 4,
ATC Code: J01GB03,
Generic name: Gentamicin,
Pharmaceutical form: infusion fluid,
Strength: 3 mg/ml,
Package: 80 ml,
Unit value: 0,24...”
Beskrivelse af udbuddet
Procurement No 4,
ATC Code: J01GB03,
Generic name: Gentamicin,
Pharmaceutical form: infusion fluid,
Strength: 3 mg/ml,
Package: 80 ml,
Unit value: 0,24 g,
Volume in units: (Iceland: 60)(Norway: 33000)(Denmark: 4750)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere
Beskrivelse af udbuddet:
“Procurement No 5,
ATC Code: J01GB03,
Generic name: Gentamicin,
Pharmaceutical form: infusion fluid,
Strength: 3 mg/ml,
Package: 120 ml,
Unit value: 0,24...”
Beskrivelse af udbuddet
Procurement No 5,
ATC Code: J01GB03,
Generic name: Gentamicin,
Pharmaceutical form: infusion fluid,
Strength: 3 mg/ml,
Package: 120 ml,
Unit value: 0,24 g,
Volume in units: (Iceland: 64)(Norway: 39000)(Denmark: 17205)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ’quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere
Beskrivelse af udbuddet:
“Procurement No 6,
ATC Code: N02BE01,
Generic name: Paracetamol,
Pharmaceutical form: infusion fluid,
Strength: 10 mg/ml,
Package: 10-50 ml,
Unit value: 3...”
Beskrivelse af udbuddet
Procurement No 6,
ATC Code: N02BE01,
Generic name: Paracetamol,
Pharmaceutical form: infusion fluid,
Strength: 10 mg/ml,
Package: 10-50 ml,
Unit value: 3 g,
Volume in units: (Iceland: 1)(Norway: 21667)(Denmark: 1817)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Vis mere
Beskrivelse af udbuddet:
“Procurement No 7,
ATC Code: N02BE01,
Generic name: Paracetamol,
Pharmaceutical form: infusion fluid,
Strength: 10 mg/ml,
Package: 100 ml,
Unit value: 3...”
Beskrivelse af udbuddet
Procurement No 7,
ATC Code: N02BE01,
Generic name: Paracetamol,
Pharmaceutical form: infusion fluid,
Strength: 10 mg/ml,
Package: 100 ml,
Unit value: 3 g,
Volume in units: (Iceland: 880)(Norway: 21667)(Denmark: 10688)
The above pharmaceuticals are put up for tender independently of the pharmaceuticals under the other procurement numbers.
Each procurement number is considered a separate lot. A supplier may thus choose to submit tender for one, several or all procurement numbers, and award will take place separately for each individual procurement number. Reference is made to the tender specifications, including the provisions on submission of tender under the individual procurement numbers.
Under the title ‘quantity in units’, an estimated consumption of the pharmaceuticals is indicated for each of the countries.
It should be noted that this estimate is based on historic consumption data and that the suppliers must expect that the actual purchase under a framework agreement may differ significantly from the estimate. Reference is made to Paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
The supplier must have authorisation to produce, import or receive pharmaceuticals for wholesale distribution within the EU/EEA.
Marketing authorisations applicable for Denmark, Norway and Iceland must be in place for the pharmaceuticals in sufficient time to ensure that the pharmaceuticals appear in Medicinpriser.dk (Denmark), ‘Farmalogg’ (Norway) and ‘Lyfjaverðskrá’ (Iceland) no later than 1.12.2019. The requirement regarding ‘Lyfjaverðskrá’ (Iceland) only apply if Iceland is part of the framework agreement, see Section II.2.11).
Procedure Oplysninger om rammeaftalen
Indkøbet indebærer, at der indgås en rammeaftale
Administrative oplysninger
Tidligere offentliggørelse vedrørende denne procedure: 2019/S 073-172191
Tildeling af kontrakt
1️⃣
Partiets identifikationsnummer: 1
Titel: 1
Dato for indgåelse af kontrakten: 2019-08-08 📅
Oplysninger om udbud
Antal modtagne bud: 2
Navn og adresse på kontrahenten
Navn: Fresenius Kabi
Postby: København
Land: Danmark 🇩🇰
Region: Hovedstaden🏙️
Entreprenøren er en SMV
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 1 050 000 💰
Kontraktens/parcellens samlede værdi: EUR 1 086 615 💰
2️⃣
Kontraktnummer: 2
Partiets identifikationsnummer: 2
Titel: 2
Oplysninger om udbud
Antal modtagne bud: 3
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 200 000 💰
Kontraktens/parcellens samlede værdi: EUR 200 206 💰
3️⃣
Kontraktnummer: 3
Partiets identifikationsnummer: 3
Titel: 3
Oplysninger om udbud
Antal modtagne bud: 1
Navn og adresse på kontrahenten
Navn: B. Braun Medical A/S
Postby: Frederiksberg
Oplysninger om kontraktens/parcellens værdi (ekskl. moms)
Anslået samlet værdi af kontrakten/partiet: EUR 250 000 💰
Kontraktens/parcellens samlede værdi: EUR 213 951 💰
“This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to...”
This call for tenders is conducted as an open procedure in accordance with the Danish Procurement Act (udbudsloven). The procurement procedure is subject to Danish law and any complaints of the procurement procedure shall be lodged with the Danish Complaints Board for Public Procurement (Klagenævnet for udbud), see Section VI.4.3).
In relation to Section II.2.4) it should be noted that the contracting authorities has considered whether the procurement group can be further subdivided. The contracting authorities has assessed that this is not the case on the basis of considerations of economies of scale which will not be realisable in case of a further subdivision, as well as costs and patient safety considerations related to the subsequent management of contract and pharmaceuticals.
In relation to Sections II.1.5) and II.2.6) it should be noted that the estimated value indicated in Section II.1.5) is the total estimated value of all procurement numbers (lots) for the duration of the framework agreement, including the option of renewal, see Section II.2.7). Section II.2.6) sets out the estimated value for each procurement number, including the option of renewal, see Section II.2.7) The value is based on the AIP (‘Apotekernes Indkøbspris’ published by the Danish Medicines Agency) of the pharmaceuticals. It should furthermore be noted that the estimated value is based on historic consumption data and that the actual purchase under a framework agreement may differ significantly from the estimate, see Section II.2.4), paragraph 3.6 of the tender specifications and clause 2 of the framework agreement.
Questions concerning the tender documents must be submitted through the tendering system, see the provisions of the tender specifications in this regard.
The access to submit tender requires that the operator is registered as a user of Amgros' tendering system. The registration as a user may take a few days, and the tenderer must therefore make sure to register in good time. Reference is made to the information provided in the tendering system, including the user guide.
In relation to Section VI.2) it should be noted that electronic invoicing is required.
Vis mere Gennemgangsprocedure
Præcise oplysninger om fristerne for gennemgangsprocedurer:
“Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act No 593 of 2.6.2016 as amended) the following deadlines apply to the lodging...”
Præcise oplysninger om fristerne for gennemgangsprocedurer
Pursuant to the Danish Act on the Complaints Board for Public Procurement (Act No 593 of 2.6.2016 as amended) the following deadlines apply to the lodging of complaints:
Complaints of the tendering procedure must be lodged with the complaints board for public procurement within 6 months after the contracting entity has entered into a framework agreement calculated from the day after the day when the contracting entity has notified the affected applicants and tenderers, see Section 7(2), para. (3) of the Act. Not later than at the time of lodging a complaint with the Danish Complaints Board for Public Procurement, the complainant must notify the contracting authorities in writing that a complaint has been lodged with the Danish Complaints Board for Public Procurement and whether the complaint was lodged during the standstill period, see Section 6(4) of the Act. In cases where the complaint was not lodged within the standstill period, the complainant must furthermore indicate whether a suspensory effect of the complaint has been requested, see clause 6(4) of the Act.
Vis mere
Kilde: OJS 2019/S 157-387539 (2019-08-12)